The Ensign Group, Inc.

The Ensign Group, Inc.

ENSGNYSE / NASDAQHealthcareSmall cap

$176.32-$0.27 (-0.2%)

Last close · Data as of Nov 20, 2026

Market cap
$9.6B
P/E
27.9x
EV / EBITDA
19.9x
Revenue
$5.1B
Net margin
6.8%
ROCE
9.3%

-1.7% over the last year

The Ensign Group, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+0.2%
3M
-2.0%
6M
-1.1%
1Y
-1.7%
5Y
+119.5%

52-week range

Day change -$0.27 (-0.2%) from $177 to $176 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ENSG, bought on each weekday since 2021.

News & filings

What The Ensign Group filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was 58.0 times interest costs.

Concerns

No concern stands out for this company on the data on file.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

The Ensign Group, Inc. provides skilled nursing, senior living, and rehabilitative services. It operates through two segments: Skilled Services and Standard Bearer.

Read moreShow less

The Ensign Group, Inc. provides skilled nursing, senior living, and rehabilitative services. It operates through two segments: Skilled Services and Standard Bearer. The Skilled Services segment provides short and long-term nursing care services for patients with chronic conditions, prolonged illness, and the elderly; specialty care, such as on-site dialysis, ventilator care, cardiac, and pulmonary management; and standard services, such as room and board, special nutritional programs, social services, recreational activities, entertainment, and other services. The Standard Bearer segment leases post-acute care properties to healthcare operators. In addition, the company operates senior living units; and provides ancillary services consisting of digital x-ray, ultrasound, electrocardiograms, sub-acute services, dialysis, respiratory, and long-term care pharmacy and patient transportation to people in their homes or at long-term care facilities, as well as mobile diagnostics. The company operates healthcare facilities in Alabama, Alaska, Arizona, Colorado, Idaho, Iowa, Kansas, Oregon, Nebraska, Nevada, South Carolina, Tennessee, Texas, Utah, Washington, and Wisconsin. The company was incorporated in 1999 and is based in San Juan Capistrano, California.

Sector
Healthcare
Shares outstanding
57.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$9.6B
P/E
27.9x
P/B
4.3x
EV / EBITDA
19.9x
EV / Sales
2.2x
P/S
1.9x
52-week high
$215.83
52-week low
$147.13

Profitability

Operating margin
8.4%
Net margin
6.8%
EBITDA margin
11.2%
ROE
15.4%
ROCE
9.3%
ROIC
8.9%
ROA
6.3%
Asset turnover
0.93

Growth

Revenue
$5.1B
Revenue growth, 1Y
18.7%
Revenue CAGR, 3Y
18.7%
Net profit growth, 1Y
15.4%
Free cash flow
$370.7M

Solvency

Current ratio
1.42
Debt / Equity
0.99
Debt / Assets
0.40
CFO / Net profit
1.64
Cash / Market cap
5.2%

Where the revenue went

Of every $100 of FY2025 revenue, $7 was left as net income.

The Ensign Group, Inc. income statement flow, FY2025
The Ensign Group, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$4.3B
RevenueGross profit$799.4M
Gross profitSelling, general and administrative$269.8M
Gross profitOther operating expenses$104.3M
Gross profitOperating income$425.3M
Operating incomePretax income$425.3M
Interest and other incomePretax income$30.3M
Pretax incomeTax and other$111.6M
Pretax incomeNet income$344.0M

Revenue and net profit

Revenue grew 18.7% in FY2025; net profit is the dashed line.

The Ensign Group, Inc. revenue and net profit by fiscal year
The Ensign Group, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$3.0B$224.7M
FY2023$3.7B$209.4M
FY2024$4.3B$298.0M
FY2025$5.1B$344.0M

Cash flows

FY2025: $564.3M from operations, $370.7M free after investment (dashed).

The Ensign Group, Inc. operating and free cash flow by fiscal year
The Ensign Group, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$272.5M$185.0M
FY2023$376.7M$270.5M
FY2024$347.2M$188.9M
FY2025$564.3M$370.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$5.1B+18.7%1Y
EBITDA
$567.9M+18.7%1Y
Net profit
$344.0M+15.4%1Y
Cash from operations
$564.3M+62.5%1Y
Free cash flow
$370.7M+96.2%1Y
Revenue CAGR, 3Y
18.7%
Net profit CAGR, 3Y
15.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$5.1B$567.9M$344.0M$370.7M15.4%+18.7%+15.4%

Monthly returns

Month-by-month returns of ENSG across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$5.5B
Liabilities$3.2B
Equity$2.2B
Paid-in capital$614.7M
Retained earnings$1.8B
Treasury stock$139.2M
Minority interest$3.1M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ENSG highlighted.

P/E against peers

ENSG trades at 27.9x earnings against a peer median of -24.3x.

  1. The Ensign Group, Inc. (this company)27.9x

Not shown (no positive earnings and no EV / Sales): Nuvalent, Inc., Praxis Precision Medicines, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
The Ensign Group, Inc.ENSGthis company$9.6B27.9x4.3x15.4%19.9x
Axsome Therapeutics, Inc.AXSM$11.9B-65.0x134.9x-207.5%-70.2x
Madrigal Pharmaceuticals, Inc.MDGL$11.4B-39.4x18.9x-47.8%-43.5x
Arrowhead Pharmaceuticals, Inc.ARWR$10.6B-6491.0x22.7x-0.3%65.9x
Cytokinetics, IncorporatedCYTK$9.8B——119.0%—
ImmunityBio, Inc.IBRX$7.6B-21.7x-15.3x70.2%-36.1x
Nuvalent, Inc.NUVL$7.4B-17.5x5.9x-34.1%—
Praxis Precision Medicines, Inc.PRAX$7.4B-24.3x8.4x-34.5%-21.5x
HealthEquity, Inc.HQY$7.2B33.4x3.4x10.2%16.1x
Peer median—-24.3x8.4x-17.2%-28.8x

Year-to-date ROI

ENSG since 1 January, against earlier years.

Historical volatility

ENSG's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

The Ensign Group, Inc. operating margin by fiscal year
The Ensign Group, Inc. operating margin by fiscal year
DateOperating margin
FY20229.8%
FY20236.8%
FY20248.4%
FY20258.4%
LineFY2025
Cost of revenueCost Of Revenue$4.3B
Gross profitGross Profit$799.5M
Operating expensesOperating Expense$374.1M
Depreciation and amortisationDepreciation And Amortization In Income Statement$104.3M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$104.3M
Rent expense supplementalRent Expense Supplemental$239.3M
Total expensesTotal Expenses$4.6B
Operating incomeOperating Income$425.3M
Pretax incomePretax Income$455.6M

Learn while you research

Academy chapters picked for The Ensign Group, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →